Published in Gene Therapy Weekly, April 11th, 2002
The agreement provides Abbott with license rights and specifies an upfront payment to Myriad, plus guaranteed research funding and potential milestones totaling approximately $34 million plus royalties.
"We are very pleased to be using our advanced biopharmaceutical technologies in collaboration with Abbott in our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.